Track topics on Twitter Track topics that are important to you
Results of the VIVA trial show that a program of three screening tests--for abdominal aortic aneurysm, peripheral arterial disease, and hypertension--resulted in a significant reduction in all-cause mortality at 5 years.
Medscape Medical News
Original Article: 'Triple' Screening for AAA, PAD, High BP Reduces MortalityNEXT ARTICLE
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...